Advances in tau-based drug discovery

Expert Opinion on Drug Discovery

Volumn 6, Issue 8, 2011, Pages 797-810

  Noble, Wendy ^a   Pooler, Amy M ^a   Hanger, Diane P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aggregation; Alzheimer's disease; Autophagy; Chaperone; Immunotherapy; Phosphorylation; Tau; Tauopathy; Therapeutic

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 3 AMINOPYRAZINYL 2 CARBOXAMIDE; 4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; ALSTERPAULLONE; AMINOTHIENOPYRIDAZINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; AR A 014418; AZD 1080; CYANINE DYE; DAUNORUBICIN; DOXORUBICIN; EPALRESTAT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDIRUBIN; LITHIUM CHLORIDE; MALEIMIDE DERIVATIVE; METHYLENE BLUE; OXINDOLEQUINAZOLINE; PACLITAXEL; PACLITAXEL DERIVATIVE; PAULLONE; PHENOTHIAZINE; PROTEIN SERINE THREONINE KINASE INHIBITOR; REMBER; SRN 003 556; TAU PROTEIN; THIADIAZOLIDINONE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AUTOPHAGY; COGNITIVE DEFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GAIN OF FUNCTION MUTATION; GLIOSIS; HUMAN; IMMUNE SYSTEM; LOSS OF FUNCTION MUTATION; MICROTUBULE; MOLECULAR BIOLOGY; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; TAUOPATHY;

EID: 79960544589     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.586690     Document Type: Review

References (112)

1. Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener 2009;4:13
2. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimers disease and related disorders. Nat Rev Neurosci 2007;8:663-72 Available from: www.alz.co.uk/dementia [Last accessed 4 April 2011] (Pubitemid 47283144)
3. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010;68:270-81
4. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:8098-102 (Pubitemid 23260862)
5. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimers disease. Nat Genet 2009;41:1088-93
6. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimers disease. Nat Genet 2009;41:1094-9
7. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-5
8. Wolfe MS. Tau mutations in neurodegenerative diseases. J Biol Chem 2009;284:6021-5
9. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimers disease mouse model. Science 2007;316:750-4 (Pubitemid 46717684)
10. Rapoport M, Dawson HN, Binder LI, et al. Tau is essential to beta -amyloidinduced neurotoxicity. Proc Natl Acad Sci USA 2002;99:6364-9 (Pubitemid 34493317)
11. Ittner LM, Gotz J. Amyloid-beta and tau - a toxic pas de deux in Alzheimers disease. Nat Rev Neurosci 2011;12:65-72
12. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease. Brain 2009;132:1355-65
13. Hanger DP, Seereeram A, Noble W. Mediators of tau phosphorylation in the pathogenesis of Alzheimers disease. Expert Rev Neurother 2009;9:1647-66
14. Takanashi M, Mori H, Arima K, et al. Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. Brain Res Mol Brain Res 2002;104:210-19
15. Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 2008;5:443-57 (Pubitemid 351952490)
16. Takashima A, Murayama M, Murayama O, et al. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci U S A 2002;95:9637-9641 (Pubitemid 28506284)
17. Sontag E, Nunbhakdi-Craig V, Lee G, et al. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem 1999;274:25490-8
18. Kampers T, Friedhoff P, Biernat J, et al. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett 1996;399:344-9 (Pubitemid 26426879)
19. Li W, Wang XS, Qu MH, et al. Human protein tau represses DNA replication in vitro. Biochim Biophys Acta 2005;1726:280-6 (Pubitemid 41668536)
20. Brandt R, Leger J, Lee G. Interaction of tau with the neural plasma membrane mediated by taus amino-terminal projection domain. J Cell Biol 1995;131:1327-40
21. Pooler AM, Usardi A, Evans CJ, et al. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging 2011;published online 7 March 2011, doi:10.1016/j. neurobiolaging.2011.01.005
22. Reynolds CH, Garwood CJ, Wray S, et al. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem 2008;283:18177-86
23. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimers disease mouse models. Cell 2010;142:387-97
24. Hanger DP, Byers HL, Wray S, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 2007;282:23645-54 (Pubitemid 47311907)
25. Lebouvier T, Scales TM, Williamson R, et al. The microtubule-associated protein tau is also phosphorylated on tyrosine. J Alzheimers Dis 2009;18:1-9
26. Schneider A, Biernat J, von Bergen M, et al. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999;38:3549-58
27. Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimers disease. Neurochem Int 2011, published online 6 Jan 2011, doi:10.1016/j.neuint.2010.12.023
28. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimers disease and related tauopathies. Nat Rev Drug Discov 2009;8:783-93
29. Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimers disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 1996;2:783-7 (Pubitemid 26225094)
30. Mandelkow EM, Stamer K, Vogel R, et al. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003;24:1079-85 (Pubitemid 37487885)
31. Cuchillo-Ibanez I, Seereeram A, Byers HL, et al. Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J 2008;22:3186-95
32. Berger Z, Roder H, Hanna A, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007;27:3650-62 (Pubitemid 46557687)
33. Ramsden M, Kotilinek L, Forster C, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005;25:10637-47 (Pubitemid 41681911)
34. Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005;309:476-81 (Pubitemid 40994688)
35. Andorfer C, Acker CM, Kress Y, et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005;25:5446-54 (Pubitemid 40770926)
36. Hoover BR, Reed MN, Su J, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010;68:1067-81
37. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996;93:8455-9 (Pubitemid 26269579)
38. Leclerc S, Garnier M, Hoessel R, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimers disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001;276:251-60 (Pubitemid 32050314)
39. Leost M, Schultz C, Link A, et al. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem 2000;267:5983-94
40. Martinez A, Alonso M, Castro A, et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK- 3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimers disease. J Med Chem 2002;45:1292-9 (Pubitemid 34263565)
41. Coghlan MP, Culbert AA, Cross DA, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793-803
42. Bhat R, Xue Y, Berg S, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937-45 (Pubitemid 37432740)
43. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001;280:720-5 (Pubitemid 32924489)
44. Engel T, Goni-Oliver P, Lucas JJ, et al. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 2006;99:1445-55 (Pubitemid 44924224)
45. Leroy K, Ando K, Heraud C, et al. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis 2010;19:705-19
46. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005;102:6990-5 (Pubitemid 40675429)
47. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimers disease amyloid-beta peptides. Nature 2003;423:435-9 (Pubitemid 36626994)
48. Hampel H, Ewers M, Burger K, et al. Lithium trial in Alzheimers disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009;70:922-31
49. Selenica ML, Jensen HS, Larsen AK, et al. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol 2007;152:959-79 (Pubitemid 350100498)
50. Martin L, Magnaudeix A, Esclaire F, et al. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Brain Res 2009;1252:66-75
51. Bhat R, Berg S, Burrows J, Lindquist J. GSK-3 inhibitors for the treatment of Alzheimers disease. In topics in medicinal chemistry: alzheimers disease. Springer; 2007
52. Yeh PA, Chang CJ, Tu PH, et al. Phosphorylation alters tau distribution and elongates life span in Drosophila. J Alzheimers Dis 2010;21:543-56
53. Martinez A, Perez DI. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimers disease? J Alzheimers Dis 2008;15:181-91
54. Duka T, Duka V, Joyce JN, Sidhu A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinsons disease models. FASEB J 2009;23:2820-30
55. Sereno L, Coma M, Rodriguez M, et al. A novel GSK-3beta inhibitor reduces Alzheimers pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009;35:359-67
56. Hu S, Begum AN, Jones MR, et al. GSK3 inhibitors show benefits in an Alzheimers disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 2009;33:193-206
57. Hernandez F, Perez M, Lucas JJ, et al. Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimers disease. J Biol Chem 2004;279:3801-6 Available from: http://www.astrazeneca. com/article/511390.aspx [Last accessed 26 February 2011] (Pubitemid 38140625)
58. Le Corre S, Klafki HW, Plesnila N, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci USA 2006;103:9673-8 (Pubitemid 43955883)
59. Engmann O, Giese KP. Crosstalk between Cdk5 and GSK3beta: implications for Alzheimers disease. Front Mol Neurosci 2009;2:2
60. Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 1993;61:921-7 (Pubitemid 23241228)
61. Planel E, Yasutake K, Fujita SC, Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem 2001;276:34298-306
62. Li L, Sengupta A, Haque N, et al. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 2004;566:261-9 (Pubitemid 38625969)
63. Available from: http://www. signumbiosciences.com/pipeline.html [Last accessed 26 February 2011]
64. Congdon EE, Duff KE. Is tau aggregation toxic or protective? J Alzheimers Dis 2008;14:453-7
65. Crowe A, Huang W, Ballatore C, et al. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 2009;48:7732-45
66. Crowe A, Ballatore C, Hyde E, et al. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun 2007;358:1-6 (Pubitemid 46719073)
67. Pickhardt M, von Bergen M, Gazova Z, et al. Screening for inhibitors of tau polymerization. Curr Alzheimer Res 2005;2:219-26 (Pubitemid 40862884)
68. Taniguchi S, Suzuki N, Masuda M, et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 2005;280:7614-23 (Pubitemid 40349654)
69. Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging 2009;13:367-9
70. OLeary JC III, Li Q, Marinec P, et al. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener 2010;5:45
71. Chang E, Congdon EE, Honson NS, et al. Structure-activity relationship of cyanine tau aggregation inhibitors. J Med Chem 2009;52:3539-47
72. Congdon EE, Figueroa YH, Wang L, et al. Inhibition of tau polymerization with a cyanine dye in two distinct model systems. J Biol Chem 2009;284:20830-9
73. Chirita C, Necula M, Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 2004;43:2879-87 (Pubitemid 38327819)
74. Ballatore C, Brunden KR, Piscitelli F, et al. Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation. J Med Chem 2010;53:3739-47
75. Pickhardt M, Gazova Z, von Bergen M, et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimers paired helical filaments in vitro and in cells. J Biol Chem 2005;280:3628-35 (Pubitemid 40223830)
76. Khlistunova I, Biernat J, Wang Y, et al. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006;281:1205-14
77. Khlistunova I, Pickhardt M, Biernat J, et al. Inhibition of tau aggregation in cell models of tauopathy. Curr Alzheimer Res 2007;4:544-6 (Pubitemid 350248387)
78. Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006;29:1538-44 (Pubitemid 44127578)
79. Bulic B, Pickhardt M, Schmidt B, et al. Development of tau aggregation inhibitors for Alzheimers disease. Angew Chem Int Ed Engl 2009;48:1740-52
80. Salminen A, Ojala J, Kaarniranta K, et al. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimers disease. Prog Neurobiol 2010;published online 5 Nov 2010, doi:10.1016/j.pneurobio.2010.10.006
81. Dickey CA, Dunmore J, Lu B, et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 2006;20:753-5 (Pubitemid 46671204)
82. Dickey CA, Kamal A, Lundgren K, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007;117:648-58 (Pubitemid 46348523)
83. Luo W, Dou F, Rodina A, et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci USA 2007;104:9511-16 (Pubitemid 47185810)
84. Berger Z, Ravikumar B, Menzies FM, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 2006;15:433-42 (Pubitemid 43159895)
85. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007;27:9115-29 (Pubitemid 47312068)
86. Boimel M, Grigoriadis N, Lourbopoulos A, et al. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010;224:472-85
87. Zhang B, Maiti A, Shively S, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 2005;102:227-31 (Pubitemid 40094457)
88. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006;24:1633-42 (Pubitemid 46638788)
89. Matsuoka Y, Gray AJ, Hirata-Fukae C, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimers disease at early pathological stage. J Mol Neurosci 2007;31:165-70 (Pubitemid 46742300)
90. Shiryaev N, Jouroukhin Y, Giladi E, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009;34:381-8
91. Matsuoka Y, Jouroukhin Y, Gray AJ, et al. A neuronal microtubule- interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimers disease. J Pharmacol Exp Ther 2008;325:146-53 (Pubitemid 351439178)
92. Melnikova I. Therapies for Alzheimers disease. Nat Rev Drug Discov 2007;6:341-2
93. Brunden KR, Zhang B, Carroll J, et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 2010;30:13861-6
94. Kalbfuss B, Mabon SA, Misteli T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem 2001;276:42986-93
95. Rodriguez-Martin T, Garcia-Blanco MA, Mansfield SG, et al. Reprogramming of tau alternative splicing by spliceosome-mediated RNA transsplicing: implications for tauopathies. Proc Natl Acad Sci USA 2005;102:15659-64 (Pubitemid 41528112)
96. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54 (Pubitemid 36818745)
97. Dodel R, Neff F, Noelker C, et al. Intravenous immunoglobulins as a treatment for Alzheimers disease: rationale and current evidence. Drugs 2010;70:513-28
98. Oddo S, Vasilevko V, Caccamo A, et al. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 2006;281:39413-23 (Pubitemid 46041901)
99. Brunden KR, Ballatore C, Crowe A, et al. Tau-directed drug discovery for Alzheimers disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 2010;223:304-10
100. Hu WT, Chen-Plotkin A, Arnold SE, et al. Biomarker discovery for Alzheimers disease, frontotemporal lobar degeneration, and Parkinsons disease. Acta Neuropathol 2010;120:385-99
101. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimers disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560-74
102. Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimers disease. Biomark Med 2010;4:51-63
103. de Leon MJ, DeSanti S, Zinkowski R, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006;27:394-401 (Pubitemid 43185324)
104. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355:2652-63 (Pubitemid 44969124)
105. Miyoshi M, Shinotoh H, Wszolek ZK, et al. In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. Parkinsonism Relat Disord 2010;16:404-8
106. Rojo LE, Alzate-Morales J, Saavedra IN, et al. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimers disease. J Alzheimers Dis 2010;19:573-89
107. Available from: http://www.alz.org/research/diagnostic-criteria/ preclinical-recommendations.pdf [Last accessed 4 April 2011]
108. Cummings JL. Integrating ADNI results into Alzheimers disease drug development programs. Neurobiol Aging 2010;31:1481-92
109. van der Zee J, Sleegers K, Van Brockhoven C. Invited article: the Alzheimer disease-frontotemporal lobar degeneration spectrum. Neurology 2008;71:1191-7
110. Vellas B, Aisen PS. Early Alzheimers trials: new developments. J Nutr Health Aging 2010;14:293
111. Iqbal K, Flory M, Khatoon S, et al. Subgroups of Alzheimers disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005;58:748-57 (Pubitemid 41552550)
112. Available from: http://www.researchals. org/page/4746/6097/[Last accessed 26 February 2011]